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Diabetes	mellitus	provides	challenges	to	clinicians	seeking	to	optimize	the	
efficacy	of	pharmacological	therapies	for	the	management	and	prevention	of	
atherothrombotic	events.	On	the	one	hand,	it	drives	the	progression	of	
atherosclerosis,	leading	to	the	highly	thrombogenic	rupture	and	erosion	of	
plaques,	at	the	same	time	as	increasing	the	thrombogenicity	of	blood	through	
modulation	of	platelet	reactivity,	enhancement	of	plasma	coagulability	and	
impairment	of	endogenous	fibrinolysis.[1]	On	the	other	hand,	it	is	associated	
with	reduced	pharmacodynamic	action	of	traditional	oral	antiplatelet	therapies,	
aspirin	and	clopidogrel,	through	increased	platelet	turnover	and,	in	the	case	of	
clopidogrel,	impairment	of	hepatic	active	metabolite	generation,	thus	rendering	
these	therapies	less	effective	despite	the	clinical	imperative	for	more	effective	
treatment.[1]	It	was	therefore	inevitable	that	more	effective	treatments	should	
be	developed	for	diabetes	patients	as	well	as	others	at	high	risk	of	
atherothrombotic	events.	This	concept	is	well	illustrated	in	the	work	of	
Angiolillo	and	colleagues	who	here	have	compared	the	pharmacodynamic	
properties	of	prasugrel	and	ticagrelor	in	diabetes	patients.[2]	
	
		A	key	component	of	the	rationale	for	comparing	prasugrel’s	and	ticagrelor’s	
effects	in	diabetes	patients	is	the	different	patterns	of	benefits	seen	in	the	
diabetes	subgroups	in	the	pivotal	phase	3	studies	of	these	drugs	compared	to	
clopidogrel.[3,	4]	With	prasugrel,	a	particularly	marked	early	benefit	in	reduced	
thrombotic	events	was	seen	in	the	diabetes	subgroup	whereas,	with	ticagrelor,	
there	was	a	more	progressive	accrual	of	benefit	over	1	year,	including	
progressive	reduction	in	mortality.	However,	differences	in	study	design	can	
explain	much	of	the	difference	in	the	patterns	of	early	benefit:	the	clopidogrel	
regimen	was	substantially	different	between	the	two	studies,	with	prasugrel	
being	compared	to	a	300-mg	loading	dose	of	clopidogrel,	often	given	after	
completion	of	percutaneous	coronary	intervention	(PCI),	whereas	ticagrelor	was	
compared	to	pretreatment	with	a	clopidogrel	loading	dose	of	300	to	600	mg.	
Given	the	higher	thrombotic	risk	and	lesser	efficacy	of	clopidogrel	in	diabetes	
patients,	it	is	clear	that	a	300mg	loading	dose	administered	after	PCI	is	“too	little,	
too	late”	so	would	be	predicted	to	drive	a	higher	event	rate	compared	to	more	
effective	pretreatment	regimens.	Nevertheless,	it	was	important	to	establish	
whether	or	not	any	differences	in	early	and	sustained	platelet	inhibition	exist	
between	prasugrel	and	ticagrelor	in	diabetes	patients.	
	
		The	phase	3	results	for	both	prasugrel	and	ticagrelor	point	to	breakthroughs	in	
oral	antiplatelet	therapy.	The	key	to	prasugrel’s	success	is	its	more	efficient	
production	of	active	metabolite	compared	to	variable	and	unreliable	clopidogrel	
active	metabolite	production.[5]	Although	the	second	step	in	prasugrel	active	
metabolite	formation	relies	on	hepatic	cytochrome	P450	(CYP)	enzymes,	in	the	
same	way	that	both	steps	in	clopidogrel	active	metabolite	formation	do,	the	
availability	of	several	different	CYP	pathways	for	generating	prasugrel	active	
metabolite	and	the	lack	of	alternative	pathways	for	inactivation	of	prasugrel	and	
its	intermediate	metabolite	mean	that	sufficient	levels	of	this	active	metabolite	
can	be	produced	in	order	to	bind	irreversibly	to	most	of	the	P2Y12	receptors	on	
circulating	platelets.	This	irreversible	inhibition	must	occur	before	the	active	
metabolite	levels	fall	to	subtherapeutic	levels	within	a	few	hours	after	prasugrel	
absorption	as	a	consequence	of	its	short	distribution	half-life	(about	30-60	
minutes)	(Figure	1).		
	The	explanation	for	ticagrelor’s	success	is	different.	Ticagrelor	belongs	to	a	class	
of	drug	that	is	distinct	from	the	thienopyridines	prasugrel	and	clopidogrel	and	
relies	on	sustained	plasma	levels	of	both	ticagrelor	and,	to	a	lesser	extent,	its	
active	metabolite	to	provide	potent	platelet	P2Y12	inhibition	(Figure	1).[5]	As	a	
consequence	of	its	reversible	binding	to	an	allosteric	site	on	P2Y12	distinct	from	
the	ADP	binding	site,	its	inhibitory	effects	resolve	when	plasma	levels	of	
ticagrelor	and	its	active	metabolite	fall	to	subtherapeutic	levels	such	that	the	
inhibitors	dissociate	from	the	platelet	P2Y12	receptors.	Plasma	half	lives	of	6	to	
12	hours	for	both	inhibitory	molecules	ensures	consistent	and	sustained	P2Y12	
inhibition	with	twice-daily	ticagrelor	dosing.[6,	7]	Beyond	P2Y12	inhibition,	
ticagrelor	also	possesses	a	second	property,	which	is	a	weak	inhibition	of	cellular	
adenosine	uptake	via	equilibrative	nucleoside	transporter	1	(ENT-1).[8]	How	
much	this	contributes	to	the	clinical	effects	of	ticagrelor	remains	to	be	
established	but	it	may	explain	some	of	the	clinical	efficacy	as	well	as	some	of	the	
adverse	effects	such	as	dyspnea.	
	
In	their	study,	Angiolillo	et	al	demonstrate	how	the	different	pharmacokinetic	
characteristics	of	prasugrel	and	ticagrelor	lead,	in	both	cases,	to	a	high	mean	
level	of	platelet	P2Y12	inhibition	at	2	hours	after	a	loading	dose	in	diabetes	
patients.	Despite	this,	a	minority	of	the	patients	exhibited	high	platelet	reactivity	
at	this	time	point	indicating	that	they	had	not	yet	reached	a	steady	state	level	of	
platelet	inhibition.	In	the	case	of	prasugrel,	previous	studies	have	suggested	
slower	onset	of	action	in	stable	patient	populations[9,	10]	compared	to	the	
healthy	volunteer	studies	that	indicate	impressive	effect	at	1	hour	and	steady	
state	inhibition	at	2	hours	after	loading	dose.[11]	Previous	work	suggested	
ticagrelor	achieves	steady	state	inhibition	by	2	hours	in	patients	with	stable	
coronary	artery	disease,[7]	so	the	results	in	the	current	study	raise	the	question	
as	to	whether	diabetes	mellitus	might	be	associated	with	slower	absorption	of	
ticagrelor	in	some	patients.	This	is	distinct	from	the	effect	of	morphine	which	
delays	gastric	emptying	and	therefore	delays	the	intestinal	absorption	and	onset	
of	action	of	prasugrel	and	ticagrelor	in	patients	with	ST-elevation	myocardial	
infarction	undergoing	primary	percutaneous	coronary	intervention	(PPCI)	
(Figure	1).[10,	12,	13]	The	rate	of	onset	of	action	of	prasugrel	or	ticagrelor	is	
particularly	important	in	PPCI	patients	and	the	various	factors	that	lead	to	
delayed	onset	of	action	in	these	patients	support	the	use	of	parenteral	
antithrombotic	therapy	to	cover	the	time	period	during	which	the	drugs	are	
absorbed	in	order	to	prevent	acute	stent	thrombosis.	
	
		Some	doubts	are	raised	in	the	current	study	as	to	whether	or	not	ticagrelor	
provides	greater	platelet	P2Y12	inhibition	during	maintenance	therapy	compared	
to	prasugrel.	We	are	inclined	to	trust	the	results	of	the	VerifyNow	P2Y12	assay	
that	showed	a	slightly	greater	level	of	inhibition	with	ticagrelor.	There	are	
multiple	strands	of	evidence	underlying	this	opinion.	Firstly,	there	was	a	
deliberate	decision	to	develop	a	10-mg	daily	maintenance	dose	of	prasugrel	
compared	to	prasugrel	doses	of	15	mg	or	greater	in	order	to	minimize	the	excess	
of	bleeding	compared	to	clopidogrel	therapy[14]	and	this	explains	offset	of	some	
of	the	platelet	inhibition	after	the	effects	of	the	prasugrel	loading	dose	have	worn	
off.[9]	This	contrasts	with	the	decision	to	develop	a	maintenance	dose	of	
ticagrelor	that	sustains	the	high	levels	of	platelet	inhibition	seen	following	a	
loading	dose.	[6][7]	Secondly,	several	studies	have	previously	observed	higher	
levels	of	platelet	P2Y12	inhibition	with	ticagrelor	compared	to	prasugrel	
maintenance	therapy,	including	in	patients	with	diabetes	mellitus.[15]	Thirdly,	
we	have	found	the	VerifyNow	P2Y12	assay	to	be	particularly	discriminating	and	
reliable	in	assessing	therapeutic	levels	of	platelet	P2Y12	inhibition	compared	to	
some	of	the	other	assays.[6,	16]	Whether	the	observed	differences	in	long-term	
levels	of	platelet	P2Y12	inhibition	with	the	two	drugs	translate	into	relevant	
differences	in	efficacy	and	safety	outcomes	is	unknown,	particularly	in	view	of	
potential	or	actual	differences	in	effects	unrelated	to	P2Y12	inhibition,	and	this	
requires	sufficiently	powered	head-to-head	studies.	
	
			Angiolillo	et	al	demonstrate	how	prasugrel	and	ticagrelor	inhibit	not	only	ADP-
induced	platelet	aggregation	but	also	platelet	aggregation	induced	by	agonists	
activating	the	receptor	pathways	for	collagen,	thromboxane	A2	and	thrombin.	
This	reflects	the	central	role	of	the	platelet	P2Y12	receptor	in	amplifying	the	
responses	mediated	by	numerous	receptor	pathways	and	explains	why	this	
receptor	has	proven	to	be	such	a	successful	target	in	the	management	of	
cardiovascular	disease	(Figure	1).[5]	Whilst	it	is	tempting	to	infer	that	this	might	
mean	aspirin	can	be	abandoned	as	a	co-medication	with	prasugrel	or	ticagrelor,	
such	an	inference	must	be	cautioned	against	in	high-risk	patients,	such	as	those	
with	diabetes	and	history	of	acute	coronary	syndrome.	The	effects	of	aspirin	are	
additive	to	those	of	a	P2Y12	inhibitor,	particularly	with	regard	to	collagen-
induced	platelet	activation	(Figure	1),	and	the	effects	of	P2Y12	inhibition	can	be	
overwhelmed	by	high	levels	of	platelet	activation.	Consequently	it	is	important	to	
wait	for	the	results	of	clinical	studies	assessing	P2Y12	inhibitor	monotherapy	
and,	furthermore,	to	look	critically	at	results	in	subgroups	at	different	levels	of	
risk	before	judging	that	aspirin	can	be	safely	abandoned	in	high-risk	individuals.	
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Figure	legend	
Figure	1.	Absorption	and	effects	of	the	orally-active	antiplatelet	drugs	aspirin,	
clopidogrel,	prasugrel	and	ticagrelor.	A2A-	Adenosine	receptor	2A;	AA	–	
Arachidonic	acid;	ADP	–	Adenosine	diphosphate;	CAM	–	Clopidogrel	active	
metabolite;	CIM	–	Clopidogrel	inactive	metabolite;	ENT1	–	Equilibrative	
nucleoside	transporter	1;	GPVI	–	Glycoprotein	VI	receptor;	P2Y12-	Platelet	P2Y12	
ADP	receptor;	PAM	–	Prasugrel	active	metabolite;	PAR1	–	Protease-activated	
receptor	1;	PAR4	–	Protease-activated	receptor	4;	TAM	–	Ticagrelor	active	
metabolite;	TPα	–	Thromboxane	receptor	[α	isoform];	TxA2	–	Thromboxane	A2.	
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